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Introduction
Osteoarthritis (OA) is a degenerative disease of the 
synovial joints with global articular involvement, includ-
ing hyaline cartilage and subchondral bone. It is the most 
common cause of chronic pain in the elderly. Particularly, 
hip OA is one of the main causes of functional disability 
and joint pain in adults older than 55 years [1-5]. Current 
treatment strategies with either non-pharmacologic or 
pharmacologic therapies aim to reduce pain and physical 
disability and, possibly also, to limit structural deteriora-
tion of the affected joints. In the last decade the use of 
intra-articular (IA) injections of hyaluronic acid (HA) has 
become more and more popular, and recently a number 
of studies have addressed the efficacy of this therapeutic 
intervention on pain and function in hip OA [6,7]. IA in-
jections have many effects: primarily restoration of elastic 
and viscous properties of synovial fluid, but also anti-in-
flammatory and anti-nociceptive effects, as well as nor-
malization of hyaluronan synthesis by synoviocytes [8]. 
Current research in the field is aimed at investigating 
new methods for stimulating the repair of damaged carti-
lage. The most recent acquisitions regarding tissue biol-
ogy highlighted the complex regulation of growth factors 
(GFs) for the normal tissue structure and the reaction to 
tissue damage. In addition, the influence of these growth 
factors on cartilage repair has been widely investigated in 
vitro and in vivo [9-12].
Platelet-rich plasma (PRP) therapy is a feasible, mini-
mally invasive and relatively inexpensive treatment that 
allows a natural concentrate of autologous growth fac-
tors to be obtained from the blood. This therapy is widely 
experimented in different fields of medicine to test its 
potential role to enhance tissue re-generation [13-17]. In 
a recent non-controlled prospective trial, the safety, toler-
Abstract
Aim: To compare the efficacy of ultrasound-guided intra-articular (IA) treatment with platelet-rich plasma (PRP) versus 
viscosupplementation (hyaluronic acid [HA]) in hip osteoarthritis. Material and methods: A total of 43 patients affected by 
monolateral severe hip osteoarthritis (OA) were included in the study. Patients were randomized to receive either intra-articu-
lar PRP (3 ml) or HA (30 mg/2 ml; 1,000-2,900 kDa), 3 injections in total – 1/week.  Clinical assessments for each patient were 
made at baseline (T0), 4 (T1), and 16 weeks (T2) of follow-up. The primary efficacy outcome was pain reduction as measured 
by VAS and by WOMAC pain subscale. Results: Data analysis revealed that, compared to T0, in the PRP-treated group VAS 
scores significantly decreased at T1 but not at T2, thereby indicating an early effect on pain which was not maintained at a 
longer term follow-up. In the HA group a significant decrease of both VAS and WOMAC values was registered only between 
T0 and T2. Conclusions: Intra-articular PRP had an immediate effect on pain that was not maintained at longer term follow-up 
when, on the contrary, the effects of intra-articular HA  were evident. 
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Fig 1. a) Free-hand technique with US probe placed parallel 
to the femur neck;  b) sagittal US showing synovium/capsule 
(long arrow), the needle situated in the articulation  (three short 
arrows), and the femoral head (H); c) PRP  ultrasound-guided 
IA injections
ability and efficacy of PRP IA injections have been the 
subject of a preliminary report on 40 hip OA patients at 
7 weeks’ and 6 months’ follow-up [18]. More recently, 
ultrasound-guided injection of platelet-rich plasma and 
HA were used separately and in combination in hip OA 
patients in a randomized controlled study [19]. Moreo-
ver, the efficacy of ultrasound-guided intra-articular in-
jections of PRP versus HA was assessed in another study 
focused on hip OA [20].
Based on the previously reported researches in the 
field, the aim of the present study is to test the efficacy of 
PRP IA therapy as compared to HA IA treatment in terms 
of pain relief and functional recovery in a population of 
hip OA patients.
Material and methods
Consecutive patients of both genders with a diagnosis 
of hip OA, according to American College of Rheumatol-
ogy criteria [21], were enrolled in the study. Exclusion cri-
teria were the following: I and IV Kellgren and Lawrence 
scores [22]; clinical evidence of hip joint instability; previ-
ous open or arthroscopic hip surgery; history of systemic 
or local infectious, neoplastic and/or other rheumatic dis-
eases; haematological diseases (coagulopathy); severe car-
diovascular diseases; infections; immunodepression; pa-
tients in therapy with antiplatelet drugs; and patients with 
Hb values <11g/dl and platelet values <150,000/mmc. 
The study protocol was approved by the local Ethics 
Committee. The experimental protocol was carefully ex-
plained to the patients participating in the study, and their 
informed consent was obtained by signing a detailed form 
in accordance with the Declaration of Helsinki. Participants 
were randomly assigned to either the HA group or PRP 
group by an independent person who selected a sealed en-
velope 30 minutes before the intervention was due to start. 
Clinical outcome measures
Self-rated pain intensity at the moment of the evalu-
ation was measured on a 10-cm horizontal visual-ana-
logue scale (VAS), with 0 cm labeled as “no pain” and 10 
cm labeled as “worst pain I have ever had”. The Italian 
version of the Western Ontario and McMaster Universi-
ties (WOMAC) OA index [23], a self-assessment mul-
tidimensional instrument that evaluates 17 functional 
activities, 5 pain-related activities, and 2 joint stiffness 
categories in 3 different subscales, was used to measure 
dysfunction and pain. 
Platelet-rich plasma preparation
PRP was obtained following the instructions for the 
use of the Regen Kit® in the preparation of the Autolo-
gous Platelet Gel. The procedure entailed a 8-ml venous 
blood sample for each hip treated. A complete peripheral 
blood count was also collected at the time of the initial 
blood donation. The samples were centrifuged twice at 
3100 rpm (for 9 min) in order to produce 4 ml of PRP. Af-
ter turning the test-tube upside down repeatedly, so as to 
achieve a homogeneous distribution, we linked the test-
tube to the transferral and aspirated the content.
All procedures were performed in the same laborato-
ry setting. All of the open procedures were performed in 
an A-class sterile hood. Randomly one PRP unit was sent 
to the laboratory for quality analysis (platelet count and 
bacteriological test). The total number of platelets/ml in 
the PRP without leukocytes represented a mean increase 
of around 100-150% compared with whole blood values.
Therapeutic Procedure
By using a computer-generated 1:1 allocation se-
quence, patients were randomized to either receiving 
Na-HA (30 mg/2 ml of HA with molecular weight 1,000 
to 2,900 kDa) or PRP (3 ml) injections (3 injections in 
total – 1/week). For patients who satisfied the inclusion 
criteria the procedure entailed a 8-ml venous blood sam-
ple (see above). Ultrasound (GE Healthcare, Logiq P5 
pro) was used as guidance for performing the IA proce-
dure in all cases [24]. The injection was performed under 
sterile conditions by means of a 3.5 MHz convex probe. 
The patients laid supine with the hip in 15°–20° internal 
rotation, and previously to the injection, the hip region 
was scanned in order to localize the most relevant local 
landmarks such as the femoral neurovascular bundle, 
the femoral neck, the hip joint capsule, and the anterior 
synovial recess (fig 1). The probe was then aligned with 
the long axis of the femoral neck, including the acetabu-
lum and the femoral head and, by a freehand technique, a 
20-gauge (9 cm) spinal needle was then advanced under 
direct ultrasound guidance into the anterior synovial re-
cess at the junction of the femoral head and neck. Once 
the needle touched the bone it was retracted by 1 mm 
and a synovial fluid aspiration was performed previously 
to the IA injection in order to decrease dilutions of the 
injected therapy [25]. Subsequently the injection was 
performed under sonographic guidance. As an additional 
confirmation of the correctly performed procedure and 
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Fig 2. Flow-chart of the patients selection.
IA therapy placement, a distension of the joint capsule 
was registered. After a few minutes of rest, the patients 
were allowed to walk and leave the clinic. They were 
also advised to rest until the next morning and during 
the follow-up period (16 weeks); the use of any anti-in-
flammatory or analgesic medication was not allowed. In 
addition, all patients were monitored for any side effects 
due to the IA injections.
Follow-Up
All patients underwent clinical evaluation at baseline 
(T0), 4 weeks (T1) and 16 weeks (T2) after the therapeu-
tic procedure (fig 2). As a primary outcome measure, we 
considered pain reduction as measured by VAS. As sec-
ondary outcome measures, we considered pain reduction 
as measured by the WOMAC pain subscale (WOMAC 
A), and functional improvement as measured by WOM-
AC joint stiffness (WOMAC B) and disability (WOMAC 
C) subscales. All questionnaires were answered before the 
physical examination performed in the out-patient clinic.
Statistical analysis
Sample size was calculated for the primary end point. 
Assuming from a pilot study a mean difference from 
baseline of 3-points of the VAS score at T2  with an α 
error of 0.05, a β error of 0.2 the minimum sample size 
was 17 for each group. Assuming a dropout of 15%, 20 
patients per group were required. The statistical analysis 
was performed using the MedCalc version 10.2.0.0 for 
Windows. All primary and secondary outcome analyses 
were performed according to the principle of intention-
to-treat [22]. The chi-square or 2-sample t-tests were ap-
plied to compare the differences of the baseline data. A 
2-way ANOVA with group (experimental versus control) 
as the between-subjects factor, and time (T0, T1 and T2) 
as the within-subjects factor was used to detect any sig-
nificant differences between the experimental and control 
groups and within each group. A Tukey post-hoc com-
parison was used to detect any significant differences be-
tween the mean values when a significant main effect and 
interaction were found. The level of significance was set 
at p<0.05 for all analyses.
Results
A total of 43 patients were randomized into two 
groups: HA group (n=22) or PRP group (n=21). De-
mographic and clinical characteristics of the patients at 
baseline were well balanced among groups, and are sum-
marized in Table I. No complications related to the IA in-
jections were registered during the treatment and follow-
up period and all patients completed the treatment and 
performed the post-treatment assessment.
Two-way ANOVA showed a significant group 
(F=5.529; p=0.02) and time (F=7.491; p=0.001) effect 
for VAS score, and a significant group and time interac-
tion (F=5.174; p=0.007). Particularly, post hoc analysis 
revealed that VAS scores were significantly lower than 
T0 values at T1, but not at T2 in the PRP group, thereby 
indicating an immediate effect on pain of PRP which was 
afterward lost (at T2 VAS value was further reduced but 
this reduction was not statistically significant).In contrast, 
in the HA group the significance between VAS values was 
reached only between T0 and T2 values. At T2, patients in 
the HA group had lower VAS values than those in the PRP 
group, the difference being significant at the 2-sample t-
test (p=0.0004). Two-way ANOVA showed a significant 
group (F=32.070; p<0.0001) and time (F=6.036; p=0.003) 
effect for WOMAC A, while no significant group xtime 
Table I. Patient baseline characteristics.
Platelet-rich 
plasma group 
(n=21)
Hyaluronic  
acid group 
(n=22)
p
Age (year) 71.37±6.03 73.62±7.87 >0.05
Sex Female 10 13 >0.05
Male 11 9
K-L Grade II 5 7 >0.05
Grade III 16 15 >0.05
VAS 6.3 (1.56) 7.08 (2.04) >0.05
WOMAC a 55.6 8 (21.2) 46.7 (22.1) >0.05
WOMAC b 53.7 (22.7) 57.6 (26.2) >0.05
WOMAC c 59.8 (22.5) 45.9 (21.7) >0.05
K-L: Kellgren and Lawrence scores, VAS: visual-analogue scale, 
WOMAC: Western Ontario and McMaster Universities index.
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interaction effect was found (F=2.488; p=0.09). Post hoc 
analysis revealed that WOMAC A scores were signifi-
cantly lower than T0 values at T2 but not at T1 in the HA 
group (Table II). No differences between T0, T1 and T2 
values were discernible in the PRP group. 
As regards to secondary outcome measures, a signifi-
cant time (F=4.436; p=0.01) effect was found for WOM-
AC B, while no significant group (F=0.471; p=0.49) 
or group xtime interaction (F=1.653; p=0.20) effects 
were found. Significant differences at post-hoc analysis 
were found only in the HA group between T0 and T2 
values. A significant group (F=14.177; p<0.0001) and 
time (F=3.680; p=0.03) effect was found for WOMAC 
C, while no group xtime interaction effect was found 
(F=0.789; p=0.457). Again, post-hoc analysis revealed a 
significant difference between T0 and T2 values in the 
HA group. All these results are detailed in Table II.
Discussions 
The efficacy of PRP IA therapy as compared to HA on 
pain relief and functional recovery in patients with hip OA 
was tested in the present study which demonstrated an ear-
ly effect (4 weeks) of PRP treatment on hip joint pain that 
however, was not maintained at follow-up. On the contrary, 
HA produced a long term (16-weeks) pain relief and not a 
short term response. Interestingly, for all the other outcome 
measures, no significant effect could be demonstrated.
To our knowledge, only a few studies have aimed at 
comparing the response to IA treatments with PRP or 
HA in hip OA patients. Particularly, a preliminary non-
controlled prospective study supported the safety, toler-
ability and efficacy of PRP injections for pain relief and 
improved function in a limited number of patients with 
OA of the hip [20]. The main difference between that 
study and our research was the patients’ age that was sig-
nificantly higher in our study. 
More recently, ultrasound-guided injection of PRP 
and HA were used separately and in combination in hip 
OA patients in a randomized controlled study which 
demonstrated that intra-articular PRP injections offered a 
significant clinical improvement in patients with hip OA 
with a benefit that was significantly more stable up to 12 
months. Those results are partially in agreement with our 
study which showed an early effect of PRP that was not 
maintained at long term follow-up [19]. 
Furthermore, the efficacy of ultrasound-guided intra-
articular injections of PRP versus HA in hip OA was pre-
viously assessed in another study and injections of PRP 
proved to be efficacious in terms of functional improve-
ment and pain reduction but were not superior to HA in 
patients with symptomatic hip OA at 12-month follow-up 
[20]. The results of this study are partially in agreement 
with our research.
Moreover, the response to multiple PRP injections 
has been evaluated also in patients with knee degenera-
tive conditions [26] showing a statistically significant im-
provement on symptoms at 2 and 6 months’ follow-up in 
early knee OA and in the younger subjects group, with the 
worst results obtained in older patients and especially in 
Table II. Visual-Analog-Scale (VAS) and WOMAC scores at baseline (T0), 4-week (T1) and 16-weeks (T2) evaluations in the ana-
lysed groups.
Hyaluronic acid group Platelet rich plasma group
Mean ± SD (95% CI) p-valuea Mean ± SD (95% CI) p-valuea
VAS
T0 6.32±1.7 (5.527-7.113) T0 vs T1 NS 7.08±2.0 (6.067-8.100) T0 vs T1 <0.01
T1 5.27±1.6 (4.538-6.002) T0 vs T2 <0.01 4.73±3.4 (3.016-6.437) T0 vs T2 NS
T2 3.63±2.1 (2.624-4.636) T1 vs T2 NS 6.36±2.1 (5.307-7.415) T1 vs T2 NS
WOMAC A
T0 42.36±20.5 (32.757-51.963) T0 vs T1 NS 58.89±22.0 (47.952-69.837) T0 vs T1 NS
T1 29.6±13.4 (23.333-35.867) T0 vs T2 <0.01 44.27±28.8 (29.964-58.574) T0 vs T2 NS
T2 19.9±11.4 (14.553-25.247) T1 vs T2 NS 53.47±22.3 (42.391-64.554) T1 vs T2 NS
WOMAC B
T0 57.65±26.2 (45.365-69.935 T0 vs T1 NS 53.72±22.7 (42.414-65.030) T0 vs T1 NS
T1 47.69±21.2 (37.787-57.593) T0 vs T2 <0.01 46.42±27.5 (32.738-60.096) T0 vs T2 NS
T2 32.91±20.6 (23.249-42.567) T1 vs T2 NS 47.22±22.7 (35.936-58.505) T1 vs T2 NS
WOMAC C
T0 45.83±21.7 (35.663-55.991) T0 vs T1 NS 59.87±22.5 (48.683-71.057) T0 vs T1 NS
T1 39.13±17.2 (31.096-47.158) T0 vs T2 <0.01 49.13±29.1 (34.675-63.583) T0 vs T2 NS
T2 28.39±17.2 (20.360-36.420) T1 vs T2 NS 50.80±22.8 (39.480-62.122) T1 vs T2 NS
aBonferroni corrected, NS: not significant, VAS: visual-analogue scale, WOMAC: Western Ontario and McMaster Universities index, SD: 
standard deviation.
467Med Ultrason 2016; 18(4): 463-468
of 100-150% compared with whole blood values, and 
this may have limited the potential therapeutic effect.
The main limitation of the present study is its lack 
of a control group without therapy. However, we aimed 
to compare PRP injections directly with HA injections 
by means of a non-inferiority study, considering the HA 
injections as a “gold standard” IA therapy [36,37]. The 
sample size was limited to 43 patients. However, with 
this sample size, we had a β error of at least 0.2, so that 
the study demonstrated a good power. Finally, the key 
point in OA is long-term outcomes (1 year to 2 year) as 
opposed to a 3-month follow-up especially if the mecha-
nism of regeneration is proposed.
In conclusion, the treatment with IA injection of PRP 
or HA, in elderly patients with OA of the hip, has been 
proven to be safe and without risks. However, the func-
tional WOMAC and VAS  score in the HA has shown 
to be more effective in the long-term (T2) than the PRP 
group which presents only significant improvement in 
VAS scores 4 weeks after treatment (T1). Further stud-
ies are needed to confirm these results with longer fol-
low-ups especially if the mechanism of regeneration is 
proposed and in order to understand the mechanism of 
action, particular with a view to finding different platelet 
concentrations and injection timing. 
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